2-(2-aminoethoxy)-1,1-dimethoxyethane NEW

Baloxavir Marboxil Intermediate (CAS 1228258-40-9)‌
Google Keywords: Baloxavir Intermediate, CAS 1228258-40-9, Antiviral API Synthesis, Influenza Drug Intermediates, GMP Pharmaceutical Manufacturing

🌟 ‌Product Overview‌

‌Baloxavir Marboxil Intermediate‌ (CAS 1228258-40-9) is a high-purity chemical intermediate crucial for synthesizing ‌Baloxavir Marboxil‌, a cap-dependent endonuclease inhibitor approved for treating influenza A and B infections. This intermediate ensures precision and scalability in antiviral API production, meeting stringent pharmaceutical quality standards.

• ‌Primary Function‌: Acts as a key building block in the synthesis of Baloxavir Marboxil API, enabling targeted antiviral activity.

• ‌Applications‌: Influenza drug development, antiviral manufacturing, and large-scale API production.

✅ ‌Key Advantages‌

🔹 ‌Ultra-High Purity‌ | ≥99.0% (HPLC/GC verified) | Complies with ICH Q11 guidelines for intermediates.
🔹 ‌Scalable Synthesis‌ | Optimized for high-yield production with minimal impurities, reducing time-to-market.
🔹 ‌Regulatory Compliance‌ | Fully characterized by NMR, HRMS, and FTIR to support FDA/EMA submissions and GMP audits.

🧪 ‌Applications‌

1. ‌API Production‌: Enables efficient synthesis of Baloxavir Marboxil with consistent batch-to-batch quality.

2. ‌Process Optimization‌: Facilitates R&D in refining synthetic pathways for cost-effective manufacturing.

3. ‌Quality Control‌: Used in analytical method validation and stability testing during batch release.

📜 ‌Quality Assurance‌

• ‌Testing Methods‌: HPLC, GC, NMR, HRMS, and FTIR for structural confirmation and purity analysis.

• ‌Standards‌: Meets USP <1086>, EP 10.0, and ISO 9001:2015 certified manufacturing protocols.

📈 ‌Market Trends‌

The ‌global antiviral drugs market‌ is projected to grow at a ‌CAGR of 3.8%‌, reaching ‌$78.5 billion by 2030‌, driven by rising influenza outbreaks and demand for single-dose therapies like Baloxavir. This intermediate is vital for accelerating generic and novel antiviral drug development post-patent expiry.

Elevate your influenza drug production with Baloxavir Intermediate – engineered for purity, scalability, and regulatory excellence.